A new auditory brainstem implant (ABI) developed by Mass General Brigham researchers and their Swiss counterparts showed promise in people with Neurofibromatosis type 2 (NF2) and severe inner ear abnormalities.
The advanced brain implant aims to provide a more effective treatment alternative than existing options by directly stimulating the brainstem’s sound-processing region.
The study, a collaboration between Mass Eye and Ear in the US and École Polytechnique Fédérale de Lausanne (EPFL) in Switzerland, introduces a new class of soft, flexible ABIs.
The implants are designed to overcome the limitations of conventional ABIs, which often rely on rigid electrodes that offer limited auditory benefits and can cause discomfort.
The novel ABI features an elastic, multilayer construct with ultra-thin platinum electrodes and silicone, allowing it to conform closely to the brainstem’s curved surface.
Its design improves contact and precision in stimulation, enhancing auditory function.
Preclinical tests in Switzerland involved two macaques receiving the implants.
Over several months of behavioural testing, the animals consistently distinguished between different stimulation patterns, indicating high-resolution auditory perception.
The promising results suggest potential for future human application.
The development of this ABI is the result of a decade-long collaboration between Mass Eye and Ear and EPFL scientists.
Researchers believe that further tests and trials will confirm its efficacy and improved treatment options for NF2 patients and others unable to benefit from cochlear implants.
Study co-senior author Daniel Lee said: “While cochlear implants are life-changing for many, there remains a group of patients for whom current technology falls short.
“Our research lays the groundwork for a future auditory brainstem implant that could improve hearing outcomes and reduce side effects in patients who are deaf and do not benefit from the cochlear implant.”
